LXRX Stock — Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals, Inc. (LXRX)

Updated October 16, 2026.

LXRX is a Stock. Total return is -98.8% over the past 26.5 years, 803.1 points behind SPY at 704.3%.

Lexicon Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule drugs for heart failure, diabetes, obesity, and neuropathic pain. The company commercializes INPEFA (sotagliflozin) for heart failure and related conditions, and maintains pipeline candidates including LX9851 for obesity and pilavapadin for neuropathic pain through partnerships with Viatris and Bristol-Myers Squibb. The company does not currently distribute to shareholders.

LXRX performance versus SPY

Price and return data through 2026-10-16.

Total return is -98.8% over the past 26.5 years, 803.1 points behind SPY at 704.3%. Over the past year its total return — price change plus distributions reinvested — is 3.4%. Its deepest 1-year drawdown was 42.4%.

LXRX key facts

Asset type

Stock

Asset class

Equity

Inception date

04/07/2000

Distribution frequency

None

Last close

$1.52 (as of 2026-10-16)

Market cap

$676,333,020

Average volume

2006303.0

Beta

1.079

Payout ratio

0.0%

EPS

$-0.16

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LXRX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 42.4%.

Who may consider LXRX — and who may not

It is a weaker fit for investors who need monthly cash flow (LXRX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on LXRX

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions